GLP-1 receptor agonists are molecules that bind to and activate the glucagon-like peptide-1 (GLP-1) receptor, a protein found in the pancreas, brain, gut, and other tissues. The class is wide. At one end sit FDA-approved drugs with well-characterized safety profiles; at the other sit shorter research peptides studied only in the lab. Sorting out what they share and where they part ways is the place to start when reading public reporting on this category.
How researchers describe the mechanism
GLP-1 is a peptide hormone the gut produces naturally in response to food. It prompts insulin secretion in a glucose-dependent way, suppresses glucagon release, and slows gastric emptying. Research also describes it acting on receptors in the brain tied to appetite and satiety signaling. Native GLP-1 lasts only minutes in circulation, because an enzyme called DPP-4 (dipeptidyl peptidase-4) degrades it quickly.
Pharmaceutical GLP-1 receptor agonists are engineered to resist that degradation. They get there by different routes. Some are structurally derived from the Gila monster peptide exendin-4, which shares only partial sequence homology with human GLP-1 but is naturally resistant to DPP-4. Others are modified analogues of human GLP-1 itself. Either way, the clinical literature reports the same net result: a molecule that keeps activating GLP-1 receptors for hours or days instead of minutes.
Tirzepatide adds a second target. It also agonizes the GIP receptor (glucose-dependent insulinotropic polypeptide). Research comparing this dual-receptor mechanism to single-agonist approaches is ongoing. Researchers describe the dual action as potentially additive on certain metabolic signals, though the clinical picture is still being characterized.
FDA-approved compounds vs. research-grade analogues
The table below covers the main compounds discussed in this class and separates approved drugs from research-use peptides.
| Compound | Primary target(s) | Approximate half-life | Regulatory status (US) |
|---|---|---|---|
| Semaglutide | GLP-1R | ~7 days | FDA-approved (Ozempic, Wegovy, Rybelsus) |
| Liraglutide | GLP-1R | ~13 hours | FDA-approved (Victoza, Saxenda) |
| Tirzepatide | GLP-1R + GIPR | ~5 days | FDA-approved (Mounjaro, Zepbound) |
| Dulaglutide | GLP-1R | ~5 days | FDA-approved (Trulicity) |
| Exenatide | GLP-1R | ~2.4 hours (short-acting) | FDA-approved (Byetta, Bydureon) |
| Retatrutide | GLP-1R + GIPR + GcgR | Under investigation | Not approved — research only |
| CagriSema (cagrilintide + semaglutide) | GLP-1R + amylin receptor | Under investigation | Not approved — research only |
Research-grade analogues are synthesized peptides sold for laboratory and preclinical research use, not approved for human consumption. The published literature on them comes from cell and animal models. Human clinical data, where it exists at all, is from structured trials rather than general use.
What the approval record reflects
FDA approval of a GLP-1 receptor agonist marks completion of a defined regulatory pathway: Phase I–III clinical trials, manufacturing standards, labeling review, and post-market surveillance obligations. Each approved drug above carries an indication, type 2 diabetes management and/or chronic weight management, plus a defined prescribing context.
Those indications keep evolving as outcomes data accumulates. In March 2024, the FDA expanded the label for semaglutide 2.4 mg (Wegovy) to include reduction of cardiovascular risk in adults with established cardiovascular disease and overweight or obesity. The agency tied that decision to results from the SELECT cardiovascular outcomes trial (as reported by the FDA and trade coverage of the approval).
Research into the class keeps widening. Published literature describes interest in cardiovascular outcomes, potential liver-related signals, and combinations with other peptide targets. Retatrutide adds glucagon receptor agonism as a third mechanism and, as of mid-2026, remained in Phase 3 trials rather than approved. The amylin-plus-GLP-1 combination CagriSema likewise advanced through its Phase 3 REDEFINE program, with Novo Nordisk reporting that it submitted a U.S. New Drug Application for an obesity indication in December 2025 (per Novo Nordisk and trade reporting). A submission is not an approval. These are active areas of investigation, and results from ongoing trials and regulatory review will decide which compounds, if any, reach the market.
Peptideone aggregates and summarizes what is publicly reported in the literature and from regulatory agencies. Nothing here is medical advice, and the research-grade compounds described above are not approved for human use.